4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) operates in the Biotechnology industry and is headquartered in Beijing, China with about 1,922 employees. Its market capitalization is roughly HK$30 billion. In the fiscal year ended 2025-12-31, 2315 reported CNY 1.4B in revenue and CNY 173M in net income.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally.
Interactive charts & full statements → Open the 2315 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 1.4B | CNY 980M | CNY 717M | CNY 534M | — |
| Gross Profit | CNY 1.0B | CNY 762M | CNY 506M | CNY 392M | — |
| Operating Income (EBIT) | CNY 279M | CNY 150M | (CNY 301M) | (CNY 602M) | — |
| Net Income | CNY 173M | CNY 34M | (CNY 383M) | (CNY 602M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 3.7B | CNY 2.4B | CNY 2.4B | CNY 2.8B | — |
| Total Liabilities | CNY 1.5B | CNY 1.6B | CNY 1.7B | CNY 1.6B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2315 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms